213250-70-5

Basic information

• Product Name: (20S)-2-methylene-19-nor-1α,25-dihydroxyvitamin D₃
• Synonyms: (20S)-2-methylene-19-nor-1α,25-dihydroxyvitamin D₃
• CAS NO: 213250-70-5
• Molecular Weight: 416.645
• Mol File: 213250-70-5.mol
• Article Data: 19

Chemical Properties

• CAS DataBase Reference: (20S)-2-methylene-19-nor-1α,25-dihydroxyvitamin D₃(CAS DataBase Reference)
• NIST Chemistry Reference: (20S)-2-methylene-19-nor-1α,25-dihydroxyvitamin D₃(213250-70-5)
• EPA Substance Registry System: (20S)-2-methylene-19-nor-1α,25-dihydroxyvitamin D₃(213250-70-5)

Safety Data

• Hazardous Substances Data: 213250-70-5(Hazardous Substances Data)

Upstream product

• 213250-59-0 methyl (3R,5R)-3,5-bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4-methylenecyclohexanecarboxylate 
• 213250-60-3 [(3R,5R)-3,5-bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4-methylenecyclohexyl]methanol 
• 213250-58-9 (3R,5R)-3,5-bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4-oxocyclohexanecarboxylic acid methyl ester 
• 135711-62-5 methyl quinicate 
• 213250-68-1 1-(1,5-dimethyl-5-triethylsilanyloxy-hexyl)-7a-methyl-octahydro-inden-4-one 
• 213250-62-5 methyl-2-((3R,5R)-3,5-bis(tertbutyldimethylsilyloxy)-4-methylenecyclohexylidene)acetate 
• 213250-63-6 2-((3R,5R)-3,5-bis(tertbutyldimethylsilyloxy)-4-methylenecyclohexylidene)ethanol 
• 213250-61-4 (3R,5R)-3,5-bis[(tert-butyldimethylsilyl)oxy]-4-methylenecyclohexanone 
• 213250-67-0 (1R,3aR,4S,7aR)-1-((S)-6-hydroxy-6-methylheptan-2-yl)-7a-methyloctahyrdo-1H-inden-4(2H)-one 
• 213250-69-2 (1R,3aS,7aR)-4-[2-[(3R,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-4-methylene-cyclohexylidene]-eth-(E)-ylidene]-1-((S)-1,5-dimethyl-5-triethylsilanyloxy-hexyl)-7a-methyl-octahydro-indene 
• 213250-64-7 [2-[(3'R,5'R)-3',5'-bis[(tert-butyldimethylsilyl)oxy]-4'-methylenecyclohexylidene]ethyl]diphenylphosphine oxide 

Relevant articles and documents

2-ALKYLIDENE-19-NOR-VITAMIN D DERIVATIVES FOR THE TREATMENT OF OSTEOGENESIS IMPERFECTA

The present invention relates to the treatment of ostogenesis imperfecta by adminstering to a patient in need thereof a 2-alkylidene-19-nor-vitamin D derivative, optionally with a bisphosphonate. Particularly, the present invention relates to the treatmen

2-Alkylidene-19-nor-vitamin D derivatives for the treatment of osteosarcoma

The present invention relates to methods of treating osteosarcoma, the methods comprising administering to a patient in need thereof a 2-alkylidene-19-nor-vitamin D derivative. Particularly, the present invention relates to methods of treating osteosarcom

2-Alkylidene-19-nor-vitamin D derivatives for the treatment of frailty, muscle damage or sarcopenia

The present invention relates to methods of treating frailty, muscle damage or sarcopenia, the methods comprising administering to a patient in need thereof a 2-alkylidene-19-nor-vitamin D derivative. Particularly, the present invention relates to methods